Cargando…

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects

Upadacitinib is a novel selective oral Janus kinase 1 (JAK) inhibitor being developed for treatment of several inflammatory diseases. Oral contraceptives are anticipated to be a common concomitant medication in the target patient populations. This study was designed to evaluate the effect of multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Mohamed‐Eslam F., Trueman, Sheryl, Feng, Tian, Friedman, Alan, Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587524/
https://www.ncbi.nlm.nih.gov/pubmed/30500075
http://dx.doi.org/10.1002/jcph.1350